Chronic Graft-versus-host Disease (cGVHD)
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Deciphera PharmaceuticalsKS - Lawrence
1 program1
VimseltinibPhase 2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
IncyteRuxolitinib
Deciphera PharmaceuticalsVimseltinib
Clinical Trials (2)
Total enrollment: 168 patients across 2 trials
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Start: Dec 2024Est. completion: Dec 2028120 patients
Phase 2Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Start: Nov 2024Est. completion: Oct 202948 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 168 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.